Strong Immune System
It is a solid “Shield” for human health
Immunity is the bodies’ own defense mechanism. It is the human body’s self-protection ability to identify and eliminate any foreign matter (virus, bacteria, etc.) that invades from the outside, deal with aging, damaged, dead, and degenerated own cells, as well as identify and deal with mutant cells and virus-infected cells in the body, thereby maintaining the health of the human body.
The book “The Autoimmune Fix” mentions: 95% of human diseases are caused by low immunity. Immunity is increased by 30%, cancer incidence and infection rates are reduced by 50%, and people are 10 years younger.
This immune system is the solid “Shield” for human health. Different people have different immune systems. Age is not the only factor in the “aging” of the immune system. Underweight or obesity, bad living habits, abnormal biochemical indicators, pregnancy and disease can all affect the immune system.
Low immunity will cause symptoms such as repeated colds, fatigue, and difficulty in wound healing. Long-term low immunity may even promote the occurrence and development of tumors.
When the immune system reacts beyond normal limits, it can cause harm to the body. When the immune system is in chaos, immune cells cannot accurately identify “self” and “foreign body” and mistakenly attack normal and harmless cells, tissues, and organs in the body, which may lead to the occurrence of autoimmune disease (AID). Therefore, maintaining immune balance can maintain human health.
148 Autoimmune Diseases
Huge unmet Clinical Needs
Colitis occurs when the immune system attacks its own colon; attacking the synovial membrane in joints, causing rheumatoid arthritis and spondylitis; attacking skin cells, causing psoriasis; attacking nerve tissue, causing damage to brain and spinal cord functions, causing allergic encephalomyelitis; attacking the beta cells responsible for producing insulin, causing type I diabetes; attacking melanocytes and causes vitiligo; attacking multiple systems, multiple tissues and organs, causing lupus erythematosus…
As of today, approximately 148 autoimmune diseases have been discovered in humans. Statistics show that autoimmune diseases affect about 5% to 8% of the world’s population, and the number of patients is estimated to be more than 500 million; there are nearly 40 million patients with major autoimmune diseases in China. From a treatment perspective, the pathogenesis of autoimmune diseases is complex and requires long-term medication. Problems such as drug resistance and compliance are common and are called “immortal cancers” that often require upgrading. This promotes the continued development of the autoimmune disease drug.
List of autoimmune diseases by the American Autoimmune
Related Diseases Association (AARDA)
The order is based on the first letter of the English
name of the disease and has nothing to do with the incidence.
1.Achalasia
2.Addison’s disease
3.Adult Still’s disease
4.Agammaglobulinemia
5.Alopecia areata
6.Amyloidosis
7.Ankylosing spondylitis
8.Anti-GBM/Anti-TBMnephritis
9.Antiphos Pholipid Syndrome，APS
10.Autoimmune angioedema
11.Autoimmune dysautonomia
12.Autoimmune encephalomyelitis
13.Autoimmune hepatitis
14.Autoimmune inner ear disease，AIED
15.Autoimmune myocarditis
16.Autoimmune oophoritis
17.Autoimmune orchitis
18.Autoimmune pancreatitis
19.Autoimmune retinopathy
20.Autoimmune urticaria
21.Axonal &neuronal neuropathy，AMAN
22.Baló disease
23.Behcet’s disease
24.Benign mucosalpemphigoid
25.Bullous pemphigoid
26.Castleman disease，CD
27.Celiac disease
28.Chagas disease
29.Chronic inflammatory demyelinating polyneuropathy，CIDP
30.Chronicrecurrent multifocal osteomyelitis，CRMO
31.Churg-Strauss Syndrome，CSS
32.Cogan’s syndrome
33.Cold agglutinin disease
34.Congenitalheart block
35.Coxsackiemyocarditis
36.CREST syndrome
37.Crohn’s disease
38.Dermatitisher petiformis
39.Dermatomyositis
40.Devic’s disease
41.Discoid lupus
42.Dressler’s syndrome
43.Endometriosis
44.Eosinophilicesophagitis，EoE
45.Eosinophilicfasciitis
46.Erythemanodosum
47.Essentialmixed cryoglobulinemia
48.Evans syndrome
49.Fibromyalgia
50.Fibrosingalveolitis
51.Giant cellarteritis
52.Giant cellmyocarditis
53.Glomerulonephritis
54.Goodpasture’s syndrome
55.Granulomatosiswith Polyangiitis，GPA
56.Graves’ disease
57.Guillain-Barre Syndrome
58.Hashimoto’sthyroiditis
59.Hemolyticanemia
60.Henoch-Schonlein purpura，HSP
61.Herpesgestationis or pemphigoid gestationis
62.HidradenitisSuppurativa
63.Hypogammaglobulinemia
64.IgANephropathy
65.IgG4-relatedsclerosing disease
66.Immunethrombocytopenic purpura，ITP
67.Inclusionbody myositis，IBM
68.Interstitialcystitis，IC
69.Juvenilearthritis
70.Juvenile myositis
71.Kawasakidisease
72.Lambert-Eaton syndrome
73.Leukocytoclasticvasculitis
74.Lichen planus
75.Lichensclerosus
76.Ligneousconjunctivitis
77.Linear IgAdisease
78.Lyme disease chronic
79.Meniere’s disease
80.Microscopic polyangiitis
81.Mixed connective tissue disease
82.Mooren’s ulcer
83.Mucha-Habermann disease
84.MultifocalMotor Neuropathy
85.Multiple Sclerosis
86.Myastheniagravis
87.Myositis
88.Narcolepsy
89.Neonatal Lupus
90.Neutropenia
91.Ocularcicatricial pemphigoid
92.Opticneuritis
93.Palindromic rheumatism
94.PANDAS
95.Paraneoplastic cerebellar degeneration
96.Paroxysmalnocturnal hemoglobinuria
97.Parry Rombergsyndrome
98.Pars planitis
99.Parsonage-Turner syndrome
100.Pemphigus
101.Peripheral neuropathy
102.Perivenous encephalomyelitis
103.Pernicious anemia
104.POEMS syndrome
105.Polyarteritis nodosa
106.Polyglandularsyndromes type I, II, III
107.Polymyalgiarheumatica
108.Polymyositis
109.Postmyocardialinfarction syndrome
110.Postpericardiotomy syndrome
111.Primarybiliary cirrhosis
112.Primary sclerosing cholangitis
113.Progesteronedermatitis
114.Psoriasis
115.Psoriatic arthritis
116.Pure red cell aplasia
117.Pyoderma gangrenosum
118.Raynaud’s phenomenon
119.Reactive Arthritis
120.Reflexsympathetic dystrophy
121.Relapsingpoly chondritis
122.Restless legs syndrome
123.Retroperitoneal fibrosis
124.Rheumatic fever
125.Rheumatoid arthritis，RA
126.Sarcoidosis
127.Schmidt syndrome
128.Scleritis
129.Scleroderma
130.Sjögren’s syndrome，SS
131.Sperm &testicular autoimmunity
132.Stiff person syndrome
133.Subacutebacterial endocarditis
134.Susac’s syndrome
135.Sympathetic ophthalmia
136.Systemic Lupus Erythematosus，SLE
137.Takayasu’s arteritis
138.Temporalar teritis
139.Thyroid eyedisease，Ted
140.Tolosa-Hunt syndrome，THS
141.Type 1 diabetes，TIDM
142.Ulcerative colitis，UC
143.Undifferentiated connective tissue disease，UCTD
144.Uveitis
145.Vasculitis
146.Vitiligo
147.Vogt-Koyanagi-HaradaDisease
148Warm autoimmune hemolytic anemia
Autoimmune diseases have long occupied the second largest disease market after cancer globally. The global autoimmune disease drug market size will be approximately US$131.7 billion in 2022. Among them, 7 drugs account for global sales of more than 5 billion US dollars and are super blockbusters. According to Frost & Sullivan, the global market size is expected to reach US$176.7 billion by 2030. The market size of China’s autoimmune disease drugs is approximately US$3.6 billion, which is less than the global sales of one product, Secukinumab, in one year.
According to data from the National Health Commission, the current number of autoimmune diseases in China is approximately 80 million. This huge patient group gives China’s autoimmune disease drug market huge potential, and also attracts big pharma and biotech to compete for investment.
Immune Disease Drug Efficacy Evaluation Model Platform
Medicilon empowers customers to leverage the market
The commercialization between local companies and giants will gradually become fiercer, autoimmune disease targets will be iterated at an accelerated pace, and new mechanism therapies will carry forward the past. How can we compete for supremacy in the future? As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon has established an autoimmune disease drug efficacy evaluation model platform to empower partners to enter the 100 billion autoimmune disease drug markets.
Rheumatoid Arthritis
When the body’s immune system is overly strong, it will
secrete many inflammatory factors, among which rheumatoid factors will attack
the immunoglobulin IgG in the body to form immune complexes and cause
inflammation. In the early stage of the disease, local joint
stiffness and pain appear, which gradually invade the whole body, and finally
lead to joint loss of function and disability throughout the body.
Medicilon models that you can choose from:
- CIA mice/rats Models
- CFA rats Models
- Carrageenan-induced acute arthritis mice/rats models
- Uric acid sodium induced gouty arthritis rats models
EAE, experimental allergic encephalomyelitis
Psoriasis
Psoriasis is a common skin disease worldwide. It is a disease that is not only closely related to genetics, but also obviously related to the environment. Its pathogenic mechanism is not yet clear.
Medicilon has established diverse models that captures key features of psoriasis, including:
- IL-23 induced hyperplasia of auricle epidermis mice
- Imiquimod induced psoriasis mice
- Vaginal epithelial mitosis mice
- Tale exfoliation mice
Atopic Dermatitis (AD)
Atopic dermatitis is a chronic, recurring, inflammatory skin disease, often accompanied by other symptoms such as allergic rhinitis, asthma, eczema, etc. The cause of the disease is not yet clear and there is no cure.
The disease related models include:
- DNFB induced chronic dermatitis mice
- DNFB & OX induced chronic dermatitis mice
- Phorbol ester induced acute eczema mice
- DNFB induced acute eczema mice
Skin score
Skin thickness
IBD, Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a group of unexplained chronic intestinal inflammatory diseases. Due to the increasing incidence, it has become a common digestive system disease and is refered to as ulcerative colitis and Crohn’s Disease.
Our IBD models includes:
- TNBS induced IBD rats
- DSS induced IBD mice
With the successive research and development of innovative drug mechanisms targeting inflammatory factors, Th17/treg balance, blocking Th2 pathways, and targeting B cells, the emergence of new immunotherapies is driving the continued development of the autoimmune disease drug. In the future, Medicilon looks forward to the launch of more domestically produced innovative drugs with new targets and new mechanisms, which will assist the research and development of drugs for autoimmune diseases and contribute to the future of human health.
